Oncology Central

Tumor heterogeneity-based resistance guides personalized cancer medicine


Recent evidence on tumor heterogeneity shapes a new era in achieving personalized cancer medicine. Indeed, despite advances in modern oncology with standardized single biopsy-based approaches, limitations still exist in predicting resistance to therapies and tumor progression.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.